SF3B3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4031126	0.87	10/20
SCHEMBL4285223	0.87	10/20
E7107 (SCHEMBL537521)	0.80	10/20
SCHEMBL1268848	0.80	10/20
SCHEMBL1268981	0.80	10/20
E7107 (SCHEMBL3624011)	0.80	10/20
SCHEMBL1268673	0.79	10/20
SCHEMBL1267796	0.78	10/20
SCHEMBL3029810	0.78	10/20
SCHEMBL3471405	0.78	10/20
SCHEMBL3280402	0.77	10/20
SCHEMBL1269115	0.77	10/20
SCHEMBL1505078	0.77	10/20
SCHEMBL1268779	0.77	10/20
SCHEMBL3620762	0.77	10/20
SCHEMBL905749	0.76	10/20
SCHEMBL1267788	0.76	10/20
SCHEMBL1504925	0.76	10/20
SCHEMBL1505052	0.76	10/20
SCHEMBL1269111	0.75	10/20

Clinical trials — most relevant to SF3B3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer	PHASE2	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Biocollection in MyeloDysplastic Syndrome (P-MDS)	nan	RECRUITING
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples	nan	RECRUITING
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping	nan	UNKNOWN
GENOMED4ALL: Improving MDS Classification and Prognosis by AI	nan	UNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)	nan	RECRUITING
SRSF2 Gene Mutation in Patients With t-MDS/AML	nan	COMPLETED
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Outcome Measures and Biomarkers in a Cohort of Spinal Muscular Atrophy Type III/ IV Patients	nan	ACTIVE_NOT_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer	nan	COMPLETED
Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Genomic Services Research Program	nan	RECRUITING
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders	nan	COMPLETED
Clinical Study of Spinal Muscular Atrophy	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Mechanisms of Cell Death in Spinal Muscular Atrophy	nan	COMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SF3B3 binder may also engage these)

Protein	Name	Similarity
A0JN52	—	1.000	A0JN52 →
Q921M3	—	1.000	Q921M3 →
Q5RBI5	—	1.000	Q5RBI5 →
Q1LVE8	—	1.000	Q1LVE8 →
P0DKL4	—	1.000	P0DKL4 →
P0DKL6	—	1.000	P0DKL6 →
Q9W0M7	—	1.000	Q9W0M7 →
Q9XYZ5	—	1.000	Q9XYZ5 →
Q7RYR4	—	0.998	Q7RYR4 →
P0CR23	—	0.998	P0CR23 →
P0CR22	—	0.997	P0CR22 →
Q4PGM6	—	0.997	Q4PGM6 →
Q52E49	—	0.997	Q52E49 →
Q9UTT2	—	0.996	Q9UTT2 →
Q9ESW0	—	0.996	Q9ESW0 →
Q4WLI5	—	0.996	Q4WLI5 →
Q5B1X8	—	0.996	Q5B1X8 →
Q6E7D1	—	0.994	Q6E7D1 →
O49552	—	0.993	O49552 →
Q6P6Z0	—	0.993	Q6P6Z0 →
DDB1	DNA damage-binding protein 1	0.992	landscape →
Q3U1J4	—	0.992	Q3U1J4 →
Q9V726	—	0.991	Q9V726 →
Q21554	—	0.991	Q21554 →
P33194	—	0.991	P33194 →
Q5R649	—	0.990	Q5R649 →
Q6QNU4	—	0.990	Q6QNU4 →
A1A4K3	—	0.990	A1A4K3 →
Q805F9	—	0.989	Q805F9 →
Q811G0	—	0.988	Q811G0 →